Hims & Hers CEO Andrew Dudum discussed the company's shift to brand-name GLP-1 drugs and the potential for AI-driven healthcare on CNBC's "Squawk Box."
These developments signal a strategic pivot for the telehealth company as it navigates regulatory scrutiny and seeks to integrate artificial intelligence into patient care.
During the interview on Tuesday, Dudum addressed the company's approach to weight-loss medications. He outlined the transition toward brand-name GLP-1 drugs as part of a broader vision to reduce overall healthcare costs for consumers [2].
Dudum also highlighted the role of artificial intelligence in the future of medicine. He said an AI health coach could be available in as little as 12 months [3]. This technology is intended to transform how patients interact with healthcare providers, and manage their long-term wellness.
Beyond product strategy, the CEO used the platform to respond to a lawsuit filed by the Federal Trade Commission. The FTC is challenging the company's data-sharing practices, a move Dudum said misunderstands the operational framework of the business [4].
The discussion took place with CNBC Squawk Box co-anchor Andrew Ross Sorkin. Dudum focused on the intersection of technology and accessibility, arguing that the current healthcare model requires modernization to remain affordable [2].
The company continues to expand its portfolio of telehealth services while defending its data policies in court. Dudum said the goal remains the reduction of barriers to medication, and professional medical advice [2].
“An AI health coach could be just 12 months away”
The integration of AI health coaches and the move toward brand-name GLP-1s suggest Hims & Hers is attempting to move from a niche telehealth provider to a comprehensive healthcare platform. However, the FTC lawsuit regarding data sharing represents a significant regulatory hurdle that could impact how the company leverages patient data to fuel its AI ambitions.
